Viking Therapeutics Inc. (NASDAQ:VKTX)

There are currently no videos for this stock.
To request coverage of this stock, please click the green request video box on the right.
Bands Volume 200 SMA 50 SMA 20 SMA Videos Alerts Articles Events
VKTX Weekly Chart

Old Forum Content for VKTX

Make a Forum Post
Become a member to view recent forum posts. Already a member? Sign in here.
Loading...
  • woodman: #Biotechs I'm focusing on (mostly for at least Q1/H1 2024) (in no particular order): $ARDX (I plan to contnue holding this through full year 2024) $EFTR $XFOR $VKTX $MREO (good buyout potential) $PDSB $INZY $CLRB (mainly for 1/8 data to be presented at JPM Healthcare Conf). Possibly some others as well such as $ORIC (I've lost focus on it and need to reacquaint myself) and $ACAD.
  • MongosPawn: $VKTX $KLG Took some profits on $VKTX. Added a little $KLG.
  • woodman: @MongosPawn $VKTX $KLG - I continue to have only small positions in the biotechs I'm interested in for 1Q24 (excluding $ARDX in which I continue to stay fully and heavily invested). Haven't pulled the triggers yet on the ones I'm eyeing up. Most still don't look too hot on the chart. VKTX has been okay but like the others, I'm not fully committed yet. As for $ARDX, I view any significant pullback as an opporunity to add to my large position.
  • Firemedic: @wineinquirer $AMZN $ELF $AMZN $AMZN $TNA $TZA $BYON $BYON $BYON $DNUT $NFLX $ARDX $NXT $ARM $INDIA $INDA $VKTX $KLG $VKTX $KLG $ARDX $AAOI $CCJ $ARM $ARM $ARM $ARM $LULU $LULU $LULU $LULU $LULU $LULU $TNA $UPRO $WFRD $ARIS $VIX $VIX $SPY $QQQ $VIX $ ...
  • woodman: @joelsg1 $GPCR $LLY - Sorry to hear that, though there could be something to be said for good safety translating into less discontinuation even where efficiacy trails other obesity drugs. I have no position and, FWIW, remain partial towards $VKTX which has obesity and NASH data coming next Q. If data aren't good, will see a similar result.
  • MongosPawn: $VKTX Added a little.
  • MongosPawn: $VKTX Got stopped out of some this morning but bought a little back on the bounce.
  • woodman: $VKTX another higher high
  • Niki: @woodman $VKTX thanks
  • woodman: @Niki $VKTX :-)
  • woodman: $LLY $NVO $VKTX et al - some evidence of a potential link between GLP-1s and lowered risk of colo-rectal cancer. https://endpts.com/new-research-points-to-potential-link-between-glp-1s-and-lowered-risk-of-colorectal-cancer/
  • woodman: $VKTX moving out of flag to continue its strong move.
  • woodman: $VKTX trying to continue its push higher. Amazing run.
  • Bridgemate: @woodman $VKTX $ALT $GPCR $TERN $ALT !!! Thank you!
  • MongosPawn: $VKTX Added small.
  • woodman: @MongosPawn $VKTX - I was wrong to sell most of mine yesterday. It's going to test the 16.30-40s resistance area. I may be chasing to buy it back....
  • woodman: @MongosPawn $VKTX - watch $TERN too (np).
  • MongosPawn: @woodman $VKTX I added again here small. Love the volume.
  • woodman: @MongosPawn $VKTX - I did buy some back on that last little pullback intraday. It was a short-lived one. These baby bio obesity drug makers getting a nice lift from recent news/data. Maybe we get back to $25 in coming weeks.
  • woodman: @mhuie $ETNB - Nice move off the bottom as it is rapidly moving to test that gap from the drop on 10/10. My sense is that many in the obesity space - and related Diabetes/liver/NASH & cardio spaces - are moving on good industry-wide obesity data ...
  • woodman: $VKTX up on news of Roche bying Carmot Therapeutics, a developer of obesity drugs. But VKTX has a better formulation. TRUIST - had note out in June Net-net, CT-388 from Carmot. "Takeover today by ROCHE However, we fail to see a clear differentiation as we think $VKTX VK2735 looks better on both efficacy and safety standpoints - also RJ a note aroumd same time."
  • curtis: @woodman $VKTX (What are your thoughts on $ALT).
  • woodman: @curtis $VKTX $ALT - I haven't been following ALT, but I believe it dropped hard over the summer on its reporting of obesity drug data associated with gastrointestinal issues - vomiting/nausea - which is something associated with its version hitting glucagon receptors. Personally, I'll be sticking with VKTX which is expected to have more obesity drug data 1Q24.
  • curtis: @woodman $VKTX $ALT Altimmune (ALT) reported strong Phase 2 trial results for its weightloss drug. ALT soared Friday https://ir.altimmune.com/news-releases/news-release-details/altimmune-announces-positive-topline-results-momentum-48-week The data in the study does cover the withdrawl of patients in study, but those that stayed lost significant weight on a pill vs shot every month.
  • woodman: @curtis $VKTX $ALT - Interesting, thanks for the info. VKTX working on a pill as well. I'll have to read up on ALT. I do believe that these baby bio obesity drug makers are attractive to BP that want a slice of the obesity pie, and we'll continue to see acquisitions in the area.
  • woodman: $VKTX - sold most of my position. Would love for gap fill back down to buy back.
  • woodman: @curtis $VKTX $ALT - I just saw this: "HC Wainwright reissued their buy rating on shares of Altimmune (NASDAQ:ALT) in a report issued on Friday, Benzinga reports. The brokerage currently has a $15.00 price objective on the stock." And here is the full link to ALT's press release. https://ir.altimmune.com/news-releases/news-release-details/altimmune-announces-positive-topline-results-momentum-48-week
  • curtis: @woodman $VKTX (Sold $ALT at $5).
  • woodman: @curtis $VKTX $ALT - One other thing, if you're looking for a similar pop on obesity data reporting, I believe the only ones in the obesity TA that are reporting data next year are $VKTX $TERN and $GPCR. I believe $VKTX is 1Q24. I need to check on all of that. I think $VKTX offers a good opportunity if I am correct about 1Q24.
  • woodman: @curtis $VKTX $ALT - Nice. I added some info in our thread below about which ones are next up for reporting obesity drug data (i.e. 2024). Take a look. They are good targets for data pops. I plan to get back into $VKTX for its expeced 1Q24 data reporting.
  • joelsg1: @woodman $VKTX $ALT $GPCR working, now above water and added. Roche bought privately held Carmot for $2.7B. $GPCR same potential.
  • woodman: @joelsg1 $VKTX $ALT $GPCR - Yep. I mentioned the buyout below and that it applies to the space broadly, IMO. It's a big pie and BP wants in. The assets are with the baby bios - As I mentioned - $VKTX $TERN and $GPCR all have more data coming in 2024.
  • woodman: $VKTX - Hmmm, I'm beginning to regret my sale of most of my position today as it moves up throught the 200d. But we'll see if it holds up through the day/tomorrow/week. Hoping for a pullback to get back in.
  • woodman: $VKTX on the rise.
  • joelsg1: @woodman $VKTX Up 25% since NASH drug data.
  • woodman: @joelsg1 $VKTX - I'm in this one.
  • woodman: The biotechs I'm in/interested in are perky today and have been perking up for the last 2 or 3 weeks for the most part. Here's an update: $ARDX (new recent high as it seems to want to climb back to the $5-plus next resistance area); $INZY (which @Lou ...
  • Lou: @woodman $ARDX $INZY $VKTX $PDSB - you're the one that deserves the shout-out @woodman. You're the reason I'm long the four above, in varying amounts. $ARDX and $INZY very long and the other two lesser holdings.
  • woodman: @Lou $ARDX $INZY $VKTX $PDSB - well, then, I *really* hope they pan out. :-) It's all good, brutha.
  • Lou: @woodman $ARDX $INZY $VKTX $PDSB - thinking about throwing in the towel on $VKTX - stubbornly holding on by fingernails. Off to the gym and will decide before EOD.
  • woodman: @Lou $ARDX $INZY $VKTX $PDSB - Let's see if we can confirm that the obesity data is coming in December. I think that will move the stock.
  • Lou: @woodman $VKTX Thanks. Patience has been my middle name and so far, it's served me well.
  • woodman: @Lou $VKTX - I currently have only a recently-purchased small position in $VKTX. But, if the obesity data is pushed off to 1Q24, I'd be less inclined to buy anymore at this time. I need to answer this question.
  • woodman: $VKTX @Lou - I just asked someone who follows VKTX closely and was told that obeisty data is now expected in 1Q24.
  • woodman: @Lou $VKTX $VKTX @Lou - I just asked someone who follows VKTX closely and was told that obeisty data is now expected in 1Q24. (I will post this above as a new post as well.)
  • sierramp: @woodman $ARDX $INZY $MREO $VKTX $XFOR $PDSB $EFTR Thanks as always for sharing your research. It is greatly appreciated.
  • woodman: @sierramp $ARDX $INZY $MREO $VKTX $XFOR $PDSB $EFTR - LIttle EFTR having a good day, and breaking out. Tons of volume today. About 8x 50d avg vol.Some very big buys today.
  • woodman: @Lou $INZY - Nice one. Many of the small biotechs are showing life. $XBI has moved above descending resistance (drawn from 6/12). See, e.g., $PDSB which has been hot. It is trying to hold its latest move up through the 200d (it easily moved up through the descending 50d a week and a half ago). $ORIC and $VKTX are holding their moves through the descending 50d so far. Another interesting one is $MREO which is high consolidation right now.
  • woodman: $PDSB $VKTX - some lively action in the biotechs.
  • woodman: $AZN $VKTX - More on Astra's strategy, including its hope of combining this early-stage potential obesity drug with its drug Farixiga (for diabetes, heart disease, and kidney disease). We'll see about all that, but the main takeaways for me is what AZN's executive VP said: "obesity is here to stay." There's a big pie with a lot of pieces to be served. https://endpts.com/astrazeneca-details-expansive-combo-strategy-for-new-oral-glp-1-as-execs-wager-obesity-market-is-here-to-stay/
  • woodman: $AZN is not giving up on the "obesity gold rush" following failure of its own drug candidate. It is paying a Chinese company for global rights to that company's very early stage oral version of an obesity drug candidate. See $VKTX which is working on an oral version too. https://www.fiercebiotech.com/biotech/astrazeneca-after-dumping-one-glp-1-drug-pays-185m-upfront-reenter-oral-obesity-gold-rush
  • bigbartabs: @woodman $AZN $VKTX ... I wonder what the next marketing gimick will be? Maybe pizza parlors handing out free anti-fat pills, with every $1000 spent on pre paid pizza coupons?
  • woodman: @bigbartabs $AZN $VKTX - Great idea. Email me to discuss a start-up.
  • woodman: @joelsg1 $GPCR - $XFOR $VKTX $PDSB - speaking of biotechs down (actually, crushed over the last whatever), I have $VKTX $XFOR and $PDSB on my potential buy back list for December catalysts. I sold all of them some time ago given their relentless beat ...
  • woodman: @joelsg1 $GPCR - I haven't followed this one. I need to look into it. That's quite a move for phase 1 results in therapeutic area with so many vying for a slice of the huge obesity pie. But my initial reaction is that perhaps we should be re-targetin ...
  • joelsg1: @woodman $GPCR $VKTX $XFOR $INZY $PDSB I wait with bated breath. Followed you into $VKTX for as I recall mixed results, but definitely think a pill is better than the injection, and duct tape across the mouth better yet. Btw, own $AMGN which has its own injectable but lasts at least 3 months per injection vs weekly for the others. Cheers.
  • woodman: @joelsg1 $GPCR $VKTX $XFOR $INZY $PDSB $AMGN - Is Amgen's still phase 1?
  • joelsg1: @woodman $GPCR $VKTX $XFOR $INZY $PDSB $AMGN In Phase 2 now.
  • woodman: @joelsg1 $GPCR $VKTX $XFOR $INZY $PDSB $AMGN - That's good.
  • MongosPawn: $VKTX Nice move but on low volume so far.
  • woodman: @MongosPawn $VKTX - nice move through the 50d and trying now to get/stay above 15.50 resistance area.
  • woodman: $VKTX - I have no position in this currently, but it is becoming interesting. Squeeze developing at 200d support as stock is about to move up through descending, but now evening out, 50d. Multiple catalysts (VK0214 X-ALD neurodegenerative disease; VK2735 obesity; VK2809 NASH) in 2H2023, but I don't know precise dates.
  • MongosPawn: $VKTX Added at the open.
  • woodman: $TERN whacked over the head after reporting data that seems decent/promising (meeting endpoint) but it's a very tough area to be in with $LLY and $NVO as blue whales. I thankfully held only a very small position, essentially a placeholder, into the data. And I've liked $VKTX's chances - I think its drug is better and safer - better than $TERN, but even with that, my VKTX position is very small currently. My smid biotech $$ are concentrated outside the obesity/metabolic processes/diabetes/NASH area right now.
  • woodman: $NVO $LLY $VKTX $TERN - Some of the second tier obesity/metabolic processes/diabetes companies - e.g. $VKTX $TERN - which have been battered post-diabetes conference (where everyone fell further in love with LLY) are rising on the LLY/NVO tides today. The $TERN $VKTX charts are ugly of late (I have only very small positions to remind me of them), but they have Q3 catalysts coming. I am trying to thread the needle with my biotech $$ with respect to catalysts/timing and shifting around my limited $$, but would consider moving some money into one or both of of VKTX and TERN. But I first want to get some data updates for $XFOR and $INZY. I may not be able to thread the needle, though.
  • woodman: @wijimmy $NANC $KRUZ $QQQ $EFTR - I don't have any more intel on EFTR. I need to look into it. My position remains small. It has two catalysts due this half of the year, but I don't know when. Some others have been of greater immediate interest to me with coming catalysts: $XFOR (I'm very interested - and have a healthy position - in this one with its much anticipated CN data coming this month or next, I'm guessing) and $INZY (one on Wednesday then next Q). $ORIC seems to be making a run into catalysts this half of the year, but I don't have a specific month even. Others of interest include these struggling ones: $TERN (catalysts this Q and another this H), $VKTX (two catalysts this H). $PDSB (one this H).
  • Aragorn: @roddog101 $ENVX $VKTX $SMCI I know nothing about the stock but this looks like a 3 bar pullback to a rising moving average in this case the 21ema. Tomorrow will tell if the 21ema is support.
  • roddog101: $ENVX closed closed not far from low of session. I am interested to see if this one does as some recent runners like $VKTX & $SMCI They ran up fast, came all the way back down then back up as $SMCI did. It makes you believe in the old saying all gaps must fill. ( I know they dont always) If $ENVX follows suit it would go to $15-17 at least. Fintwit has some rabid longs in this & you can tell by the pumpy type posts ton o weak $$ in this name. Cohodes even said it is a $2 stock or a $100-$200 stock....
  • woodman: $VKTX $TERN - both of these NASH / second tier obesity stocks are building bases after significant pullbacks following the June American Diabetes Association conference in which $LLY sucked all the oxygen out of the room regarding its obesity drug. These two stocks seem to have bottomed ahead of coming catalysts (VKTX - obesity Phase 1 data in 2H, but likely Q3 this year, as well X-ALD Phase 1b update H2 this year; TERN Q3 this year for NASH Phase 2a data). I suspect they will rise again into their catalysts.
  • joelsg1: @woodman $VKTX $TERN $LLY Lazarus stocks, think I'll wait but please keep posting about them.
  • woodman: @joelsg1 $VKTX $TERN $LLY - Funny, I traditionally call such stocks "Phoenix" stocks, but same concept. I'm waiting too (I currently have a small VKTX position and even smaller TERN position).
  • woodman: @Lou $PDSB - I have only a placeholder position currently. I had started buying it back but it fell through levels and I didn't like it, so I sold. I'd still like to buy it back for catalysts this half of the year, but I have to thread some needles w ...
  • woodman: $VKTX been buying this back yesterday and today. Not out of the woods, but I think obesity data in 3Q (though still in early phase) will be good and they've got a safer/better performing recipe (Glucagon👎 GLP-1/GIP👍 ) I think is attractive to some Pharma that desperately wants to be in the obesity/NASH arena. Doesn't have to be a buyout; can be some strategic partnerships. Data could move it decently despite the 800 pound $LLY gorilla. (I also like that VKTX has about $280 million in cash).
  • woodman: $TERN - another one with some Q3 data (NASH) expected to be good. It's stuck under the 200d right now. Like $VKTX got whacked at American Diabetes Association conference where $LLY took all the oxygen out of the room, but this one still has a presences in the big pond. It has tons of cash for a small market cap. $283 million in cash, I think.
  • woodman: @woodman $VKTX $LLY - Sorry, mispoke. Not $283 mil in cash. More like $150 mil, I think.
  • woodman: @woodman $TERN $VKTX $LLY - presence, not plural. :-?
  • MongosPawn: @woodman $VKTX $LLY Back in this morning with a starter on $VKTX.
  • joelsg1: $VKTX Sold remainder first thing am, seen this movie before with $ALT.
  • woodman: @joelsg1 $VKTX $ALT - I'm with you. I have only a small reminder position in VKTX as well. It's all about $LLY's obesity drug. Even $PFE out of favor now that it ditched one of its treatments in favor of a two a day pill, but is far behind on a one a ...
  • joelsg1: @woodman $VKTX $ALT $LLY $PFE $TERN Following your lead on these, but obvious concern that the Big Boys' oral formulations will swamp little guys like $VKTX. Also concerned about the thyroid cancer risks being studied, where hopefully $VKTX may have better profile.
  • woodman: @joelsg1 $VKTX $ALT $LLY $PFE $TERN - Very valid concerns. And the small guys are years away. Perhaps a PFE type scoops one of them up in time. Not holding my breath. The need more data.
  • woodman: @joelsg1 $VKTX $ALT $LLY $PFE $TERN - VKTX looks destined for the 11s-12s.
  • phgruver: @woodman $VKTX $ALT $LLY $PFE $TERN $PFE has been in a downtrend for over a year, peaking in Dec 2021. Part of this mimics the market, but the past 6 months, $PFE has definitely under performed. At the current price, the $.41/qtr dividend produces a 4.45% return, something to consider for income in a LT account. As one of the big dogs in that space, I would consider adding, cautiously, to $PFE as a #VALUE play.
  • woodman: Crazy day for bios today, and mostly not in a good way. I've sold a bunch of $VKTX as it has fallen through multiple levels of support. I'll revisit it after some dust settles. There are a lot cross currents in obesity (following the American Diabete ...
  • sierramp: @woodman $VKTX $LLY $NVO $PFE $TERN $XFOR As always, thanks for your informative, well thought post. Appreciate it.
  • woodman: $VKTX - drifted/consolidating into the 50d which, so far, looks like support and a bounce area as it's moving above the 8dEMA and taking a shot at the 20d/21dEMA today.
  • joelsg1: @woodman $VKTX When do you expect next data dump on NASH?
  • woodman: @joelsg1 $VKTX - potential catalysts: VK0214 small molecule thyroid hormone receptor agonist (X-ALD) Ph1b update H2 2023; VK2735 (oral formulation) (dual agonist of GLP-1 & GIP receptors) (obesity) Ph1 data readout H2 2023; VK2809 (THR-B agoinist (NASH) Ph2b data readout H1 2024.
  • joelsg1: @woodman $VKTX Thanks, appreciate you.
  • woodman: @joelsg1 $VKTX - no problem. Add as a potential short-term catalyst (though I'm not sure it will mean a ton) addition into Russell 3000 6/23 amc/open 6/26.
  • woodman: ...
    Additionally, TERN is one of the bios I'm holding over their additions into the Russell 3000 on Fri 6/23 amc (for trading in the index on Mon 6/26). Funds will have to buy it. In addition to TERN, I have several other biotechs that will be added to ...
  • woodman: @MongosPawn $XFOR - I haven't yet. Nor have I added to $ARDX yet. Still watching but admittedly distracted today due to work and personal stuff. Both are going into the Russell 3000 (along with $VKTX and $INZY and a number of others).
  • woodman: $VKTX - moving sideways into the rising 50d. Today was a green day after several reds, but this is a very stable "pullback"/drift. Closed today at 22.46 (50d is 21.55).

    What's coming? H2 of this year, expecting: (1) Ph 1b update for small ...
  • woodman: NASH & obesity (the next gen ones you don't read about) staying strong. The bulk of my investment here is in $VKTX, though I also have some $ETBN and $TERN.
  • woodman: $VKTX $ETNB $TERN - the NASH/obesity biotechs contintue to move up/back up today.
  • woodman: $TERN is next up (Q3) in the NASH therapeutic area (TA) - for its Phase 2a top line data for TERN-501 (THR-B Agonist) alone and in combo with TERN-101 (FXR Agonist) (DUET trial). Other bios focusing on NASH ($AKRO $MDGL $ETNB $VKTX) have moved well post-NASH-data reporting.
  • woodman: $VKTX continues on a nice path as it marches higher. Now up through $25. It still has 2 more catalysts coming in 2023 (H2): Phase 1 data readout for its oral obesity med (which has already shown good signs), and Phase 1b update for X-ALD (adrenomyeloneuropathy). I continue to hang onto this one.
  • joelsg1: @Docoof $PFE #CNBC #news Like the pill formulation as people hate needles, that's why I'm in $VKTX, but need comparison with LLY's drug.
  • joelsg1: $VKTX Cramer last night highlighted 4 drugs in development pipeline, in addition to pumps of $TSLA and $CELH.
  • debeers: $VKTX- Viking Therapeutics Says Phase 2b Trial for Liver Disease Drug Candidate VK2809 Meets Primary Endpoint; Shares Rise Pre-Bell 7:50 AM ET, 05/16/2023 - MT Newswires 07:50 AM EDT, 05/16/2023 (MT Newswires) -- Viking Therapeutics (VKTX) said Tuesday that its phase 2b clinical trial of VK2809 in patients with biopsy-confirmed non-alcoholic steatohepatitis, a liver disease, has met its primary endpoint. Based on the topline results of the trial, patients who received the drug candidate saw statistically significant reductions in liver fat content in 12 weeks, along with significant reductions in other plasma lipids that cause cardiovascular problems. The median relative change from baseline in liver fat was found to be from 38% to 55%, the company said.
Visit the Trading Forum to join in the discussion.
Stock Price $82.00
Change 0.00%
Volume 4,331,410

Viking Therapeutics Inc is a clinical-stage biopharmaceutical company. The Company develops therapies for metabolic and endocrine disorders. It includes portfolio of five drug candidates in clinical trials or preclinical studies.

Request Video of VKTX
Already a member? Sign in here.
Past Month

Leading Peers

Past Month

Lagging Peers

Dan Fitzpatrick

Stock Market Mentor gives you EVERYTHING you need to succeed in the market; all in one place. How easy is that? Dan Fitzpatrick and his elite community of traders share trading ideas, strategies and much more. Dan Fitzpatrick--a world class Technical Analyst, trading coach and regular CNBC contributor--gives you access to all of this with a 30 day trial membership for just $7.77. Get started TODAY and start trading better TOMORROW with the following premium content:

  • Nightly video Strategy Sessions with a game plan for tomorrow
  • Got a stock you want Dan to look at? Just ask.
  • Patent pending video alerts instantly delivered to you when one of Dan’s trading signals is triggered. This is not your typical price alert. This is a short video explaining the action you need to take to make money. No more “Woulda, coulda, shoulda”
  • Access to over 90,400 stock analysis videos
  • Access an ever expanding library (90,400) of educational videos that will save you time and make you money

Join a team of friends and traders that have one thing in common; a burning desire to succeed.

Become a Member Today!

Gain immediate access to all our exclusive articles, features, how-to's, discussion group and much more...

Satisfaction Guaranteed!

Your Stock Market Mentor membership comes with a 30 day, no questions asked, 100% money back guarantee!